SHP2 inhibitor PHPS1 ameliorates acute kidney injury by Erk1/2-STAT3 signaling in a combined murine hemorrhage

Jihong Jiang1, Baoji Hu2, Chun-Shiang Chung3

  • 1Department of Anesthesiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, P.R. China.

Abstract

Insights

Inhibiting SHP2 (Src homology 2 domain-containing phosphatase 2) with PHPS1 reduces acute kidney injury (AKI) caused by sequential hemorrhage and sepsis. This SHP2 inhibition protects kidneys by mitigating Erk1/2 and STAT3 signaling pathways.

Area of Science:

  • Nephrology
  • Immunology
  • Molecular Biology

Background:

  • Acute kidney injury (AKI) is a significant clinical problem often caused by hypovolemic shock and sepsis.
  • Src homology 2 domain-containing phosphatase 2 (SHP2) plays a crucial role in immune cell signaling and maintaining immunological homeostasis.

Purpose of the Study:

  • To investigate the role of SHP2 signaling in AKI induced by a sequential hemorrhage (Hem) and cecal ligation and puncture (CLP) model.
  • To determine if inhibiting SHP2 with phenylhydrazonopyrazolone sulfonate 1 (PHPS1) could attenuate this AKI.

Main Methods:

  • Male C57BL/6 mice underwent Hem followed by CLP, or sham procedures.
  • Kidney and blood samples were analyzed for markers of kidney injury (BUN, creatinine, NGAL), inflammation (cytokines/chemokines), and key signaling proteins (SHP2, Erk1/2, STAT3).
  • SHP2 activity was inhibited using its selective inhibitor, PHPS1.

Main Results:

  • The Hem/CLP model significantly increased markers of kidney injury and inflammation compared to controls.
  • Hem/CLP elevated levels of HMGB1 and activated SHP2, Erk1/2, and STAT3 signaling in kidney tissues.
  • PHPS1 treatment markedly reduced Hem/CLP-induced kidney injury and inflammatory responses.

Conclusions:

  • SHP2 inhibition effectively attenuates AKI in a preclinical model of combined hemorrhage and sepsis.
  • The protective effect of SHP2 inhibition is likely mediated by the suppression of Erk1/2 and STAT3 signaling pathways.
  • These findings suggest SHP2 inhibition as a potential therapeutic strategy for AKI with significant clinical implications.